DK0867178T3 - Non-allosteriske GABA A agonister til behandling af søvnforstyrrelser - Google Patents

Non-allosteriske GABA A agonister til behandling af søvnforstyrrelser

Info

Publication number
DK0867178T3
DK0867178T3 DK98102355T DK98102355T DK0867178T3 DK 0867178 T3 DK0867178 T3 DK 0867178T3 DK 98102355 T DK98102355 T DK 98102355T DK 98102355 T DK98102355 T DK 98102355T DK 0867178 T3 DK0867178 T3 DK 0867178T3
Authority
DK
Denmark
Prior art keywords
sleep disorders
agonists
treatment
allosteric gaba
allosteric
Prior art date
Application number
DK98102355T
Other languages
Danish (da)
English (en)
Inventor
Marike Lancel
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7766768&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0867178(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of DK0867178T3 publication Critical patent/DK0867178T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK98102355T 1995-07-13 1996-07-10 Non-allosteriske GABA A agonister til behandling af søvnforstyrrelser DK0867178T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19525598A DE19525598C2 (de) 1995-07-13 1995-07-13 Schlafmittel

Publications (1)

Publication Number Publication Date
DK0867178T3 true DK0867178T3 (da) 2002-02-18

Family

ID=7766768

Family Applications (3)

Application Number Title Priority Date Filing Date
DK96925704T DK0840601T3 (da) 1995-07-13 1996-07-10 THIP til behandling af søvnforstyrrelser
DK98102356T DK0867184T3 (da) 1995-07-13 1996-07-10 Anvendelse af tiagabin til behandling af søvnforstyrrelser
DK98102355T DK0867178T3 (da) 1995-07-13 1996-07-10 Non-allosteriske GABA A agonister til behandling af søvnforstyrrelser

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK96925704T DK0840601T3 (da) 1995-07-13 1996-07-10 THIP til behandling af søvnforstyrrelser
DK98102356T DK0867184T3 (da) 1995-07-13 1996-07-10 Anvendelse af tiagabin til behandling af søvnforstyrrelser

Country Status (12)

Country Link
US (1) US5929065A (ja)
EP (3) EP0867178B1 (ja)
JP (3) JP3754705B2 (ja)
AT (3) ATE207352T1 (ja)
AU (1) AU723954B2 (ja)
CA (1) CA2226582C (ja)
CL (1) CL2003002785A1 (ja)
DE (4) DE19525598C2 (ja)
DK (3) DK0840601T3 (ja)
ES (3) ES2166110T3 (ja)
PT (3) PT867184E (ja)
WO (1) WO1997002813A1 (ja)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
CA2299464C (en) * 1997-08-01 2009-02-17 Elan Corporation, Plc Controlled release pharmaceutical compositions containing tiagabine
IE970588A1 (en) 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
WO2001022941A1 (en) * 1999-09-28 2001-04-05 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
ES2300332T3 (es) * 2000-06-26 2008-06-16 Warner-Lambert Company Llc Analogos de gabapentina para trastornos del sueño.
BR0209834A (pt) * 2001-05-21 2004-06-15 Lundbeck & Co As H Produto granulado fundido, processo para a preparação do mesmo, composição, e, forma de dosagem unitária farmacêutica moldada sólida
PT1641456E (pt) 2003-06-25 2010-06-01 Lundbeck & Co As H Gaboxadol para o tratamento de depressão e outros distúrbios afectivos
AR045540A1 (es) 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
US20070032553A1 (en) * 2003-09-10 2007-02-08 Mckernan Ruth Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
ES2515092T3 (es) * 2003-12-11 2014-10-29 Sunovion Pharmaceuticals Inc. Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
TW200528098A (en) * 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
WO2005063248A1 (en) * 2003-12-22 2005-07-14 Sepracor Inc. Modafinil combination therapy for improving sleep quality
CA2551637A1 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
GB0402118D0 (en) * 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
ES2337700T3 (es) * 2004-02-18 2010-04-28 Sepracor, Inc. Terapia combinada de agonista de dopamina con sedantes para mejorar la calidad del sueño.
BRPI0509210A (pt) * 2004-04-02 2007-08-28 Lundbeck & Co As H uso de gaboxadol, e, métodos para tratar função respiratória enfraquecida, e apnéia do sono
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (en) 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPHIC FORMS OF A GABAA AGONIST
JP5380930B2 (ja) * 2007-07-24 2014-01-08 大正製薬株式会社 睡眠改善剤
MX2020012404A (es) 2014-06-06 2022-04-11 Ovid Therapeutics Inc Metodos para incrementar la inhibicion tonica y para tratar insomnio secundario.
CA2977437C (en) 2015-03-24 2023-07-04 H. Lundbeck A/S Manufacture of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
EP3324961A4 (en) 2015-07-17 2019-03-13 Ovid Therapeutics, Inc. METHOD FOR TREATING DEVELOPMENT DISORDERS WITH GABOXADOL
EP3481387A4 (en) 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
WO2019028234A1 (en) 2017-08-04 2019-02-07 Ovid Therapeutics Inc. USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
WO2020061410A1 (en) 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
EP3883566A4 (en) 2018-11-21 2022-09-07 Certego Therapeutics Inc. GABOXADOL FOR SUICIDE RISK REDUCTION AND RAPID DEPRESSION RELIEF
CA3122761A1 (en) 2018-12-14 2020-06-18 Raimondo Fazio Martial arts training device
MX2021007224A (es) 2018-12-17 2021-09-23 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del trastorno del sue?o vigilia que no es de 24 horas.
KR20220114572A (ko) 2019-12-18 2022-08-17 오비드 테라퓨틱스 인크. 1p36 결실 증후군의 치료적 치료를 위한 가복사돌
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
WO2023015395A1 (en) * 2021-08-11 2023-02-16 Psyched Wellness Ltd. Amanita muscaria extracts and compounds and their beneficial and therapeutic use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362731A (en) * 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4786647A (en) * 1986-06-30 1988-11-22 University Of Florida Method for eliciting anxiolysis
US5167228A (en) * 1987-06-26 1992-12-01 Brigham And Women's Hospital Assessment and modification of endogenous circadian phase and amplitude
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5185446A (en) * 1990-09-04 1993-02-09 Neurogen Corporation Certain cycloalkyl imidazopyrimidines; a new class of gaba brainreceptor ligands
DK58291D0 (da) * 1991-04-02 1991-04-02 Novo Nordisk As Krystalinsk stof og dets fremstilling
US6077839A (en) * 1992-03-19 2000-06-20 Allergan Sales, Inc. Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (GABA) agonists

Also Published As

Publication number Publication date
DE69616375T2 (de) 2002-07-11
PT840601E (pt) 2002-04-29
DK0840601T3 (da) 2002-02-18
EP0867184B1 (en) 2001-10-24
DK0867184T3 (da) 2002-02-18
DE69616375D1 (de) 2001-11-29
EP0840601A1 (en) 1998-05-13
ATE207352T1 (de) 2001-11-15
EP0867184A1 (en) 1998-09-30
ES2166111T3 (es) 2002-04-01
ATE207356T1 (de) 2001-11-15
EP0867178A1 (en) 1998-09-30
PT867184E (pt) 2002-04-29
DE69616376D1 (de) 2001-11-29
CL2003002785A1 (es) 2005-04-08
AU723954B2 (en) 2000-09-07
WO1997002813A1 (en) 1997-01-30
CA2226582C (en) 2008-02-19
ES2165990T3 (es) 2002-04-01
JP2009057382A (ja) 2009-03-19
AU6613796A (en) 1997-02-10
JP3754705B2 (ja) 2006-03-15
JP2005047925A (ja) 2005-02-24
PT867178E (pt) 2002-04-29
EP0840601B1 (en) 2001-10-24
JPH11509194A (ja) 1999-08-17
US5929065A (en) 1999-07-27
ES2166110T3 (es) 2002-04-01
DE69616333T2 (de) 2002-07-04
EP0867178B1 (en) 2001-10-24
CA2226582A1 (en) 1997-01-30
DE69616376T2 (de) 2002-06-27
ATE207349T1 (de) 2001-11-15
DE19525598A1 (de) 1997-01-16
DE69616333D1 (de) 2001-11-29
DE19525598C2 (de) 1997-09-25

Similar Documents

Publication Publication Date Title
DK0867178T3 (da) Non-allosteriske GABA A agonister til behandling af søvnforstyrrelser
DK1091745T3 (da) Behandling af hyperproliferative forstyrrelser
DK0934061T3 (da) Isobutylgaba og dets derivater til behandling af smerte
PT1333887E (pt) Metodo de tratamento de desordens musculares
DK0880350T3 (da) Behandling af dissemineret sklerose
EA199800866A1 (ru) Способ снятия боли
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
ATE293972T1 (de) Behandlung von chronischen schmerzen
MA26592A1 (fr) Procede et medicament utilisant des composes cycliques, pour le traitement de la bronchopneumopathie chronique obstructive
NO20010390L (no) Behandling av angstsykdommer
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DK0774961T3 (da) Anvendelse af selegilin til behandling af epileptiske lidelser
BR9708037A (pt) Método para o tratamento de abuso de substância
DK0900085T3 (da) Behandling af overdreven aggression med olanzapin
HRP20080389A2 (en) THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS
SE9501773D0 (sv) New use
NO984190L (no) FremgangsmÕte for behandling av insomnia